目的：探讨非小细胞肺癌（NSCLC）患者治疗前血清炎症反应指标及其评分系统对预后的预测价值。方法：选择2015年6月至2020年6月在我院确诊为NSCLC的患者132例为研究对象，研究结局为无复发生存期（RFS）和总生存期（OS）。采用受试者工作特征曲线（ROC曲线）分析治疗前血清中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）以及单核细胞与淋巴细胞比值（MLR）预测患者死亡的最佳临界值；多因素Cox回归分析危险因素；将NLR≥2.34、PLR≥86.9和MLR≥0.21分别计1分，否则计0分，构建评分系统（总分0～3分），用ROC曲线评价评分系统预测RFS和OS的效能。结果：132例患者中复发40例（30.3%），死亡34例（25.8%）。NLR、PLR及MLR预测死亡的最佳临界值分别为2.34、86.9和0.21。高评分（≥2分）组（50例） RFS和OS明显低于低评分（<2分）组（82例）（均P<0.05）。Cox分析显示，TNM分期Ⅱ期、低分化和评分系统≥2分均是影响RFS和OS的独立危险因素（均P<0.05）。ROC曲线分析显示，评分系统预测RFS和OS的曲线下面积分别为0.844和0.886（P<0.05）。结论：血清NLR、PLR及MLR评分系统对NSCLC患者RFS和OS的预测有较高的价值。

[1] 薛宝函,高学军,楚师成.胸腔镜下治疗早期非小细胞肺癌的现状及进展[J].现代医学,2019,47(5):627-629.
[2] 秦营.胸腔镜肺叶与亚肺叶切除术对高龄早期非小细胞肺癌患者创伤指标、免疫指标及治疗效果的影响[J].现代医学,2020,48(4):496-499.
[3] WAINER Z,WRIGHT G M,GOUGH K,et al.Impact of sex on prognostic host factors in surgical patients with lung cancer[J].ANZ J Surg,2017,87(6):1015-1020.
[4] SALMIHEIMO A,MUSTONEN H,STENMAN U H,et al.Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma[J].PLoS One,2016,11(1):e0163064.
[5] SIERZEGA M,LENART M,RUTKOWSKA M,et al.Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer[J].Ann Surg Oncol,2017,24(4):808-815.
[6] DING N,PANG Z,SHEN H,et al.The prognostic value of PLR in lung cancer,a meta-analysis based on results from a large consecutive cohort[J].Sci Rep,2016,6(2):34823.
[7] 徐朝娜,任瑛瑛,黄晓颖,等.外周血淋巴细胞/单核细胞比值、中性粒细胞/淋巴细胞比值与EGFR突变肺癌及其转移的相关性研究[J].医学研究杂志,2018,47(7):120-125.
[8] HIRAHARA N,MATSUBARA T,MIZOTA Y,et al.Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy[J].BMC Surg,2016,16(4):66.
[9] 肖跃华.胸腔镜手术对早期肺癌患者应激指标以及炎症因子的影响[J].医学理论与实践,2020,33(13):2128-2130.
[10] 吴其琛,李小平,刘一胜,等.早期周围型肺癌行胸腔镜手术后炎症反应及免疫功能的变化[J].腹腔镜外科杂志,2020,25(5):338-342.
[11] 李四香,李镭,杨茗,等.肺癌患者血常规指标特征分析[J].华西医学,2020,35(9):1060-1067.
[12] WANG Y,HU X,XU W Y,et al.Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer:a retrospective study[J].Thorac Cancer,2019,10(6):1402-1411.
[13] GU X,SUN S,GAO XS et al.Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer:evidence from 3,430 patients[J].Sci Rep,2016,6(2):23893.
[14] YIN Y,WANG J,WANG X,et al.Prognostic value of the neu-trophil to lymphocyte ratio in lung cancer:a meta-analysis[J].Clinics(Sao Paulo),2015,70(2):524-530.
[15] ZHANG H,GAO L,ZHANG B,et al.Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer:a systematic review and meta-analysis[J].Sci Rep,2016,6(2):22618.
[16] LI W,MA G,WU Q,et al.Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients:a systematic review and meta-analysis[J].Oncotarget,2017,8(4):110606-110613.
[17] 郭苗,刘玮,李伟.FIB、NLR、PLR联合检测在非小细胞肺癌早期诊断及预后评估中的价值[J].海南医学,2020,31(15):1954-1957.
[18] 孜瓦热古丽·努尔,崔笑,方若欣,等.中性粒细胞与淋巴细胞比值对非小细胞肺癌化疗近期疗效的预测价值[J].武汉大学学报(医学版),2020,41(5):750-753.
[19] 苏欢,陈明.炎症反应与肿瘤微环境对前列腺癌作用机制的研究进展[J].东南大学学报(医学版),2017,36(5):847-851.
[20] AAHIN F,ASLAN A F.Relationship between inflammatory and biological markers and lung cancer[J].J Clin Med,2018,7(7):160.
[21] LAN H,ZHOU L,CHI D,et al.Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery:a single institutional cohort study[J].Oncotarget,2017,8(5):35301-35310.
[22] 唐艳林, 王锋, 刘自刚, 等. 外周血T淋巴细胞亚群及早期炎症标志物表达对老年非小细胞肺癌化疗预后的影响分析[J/OL]. 中华细胞与干细胞杂志(电子版),2020,10(2):97-102. https://zhxbygxbzz.cma-cmc.com.cn/CN/2095-1221/home.shtml.
[23] DEMB J,WEI E K,IZANO M,et al.Chronic inflammation and risk of lung cancer in older adults in the health,aging and body composition cohort study[J].J Geriatr Oncol,2019,10(2):265-271.